Document details

Tolerogenic insulin peptide therapy precipitates type 1 diabetes

Author(s): Bergman, Marie-Louise ; Lopes-Carvalho, Thiago ; Martins, Ana-Catarina ; Grieco, Fabio A. ; Eizirik, Décio L. ; Demengeot, Jocelyne

Date: 2017

Persistent ID: http://hdl.handle.net/10400.7/820

Origin: ARCA - Access to Research and Communication Annals

Project/scholarship: info:eu-repo/grantAgreement/EC/FP7/241447/EU;

Subject(s): Animals; Autoantibodies; Diabetes Mellitus, Type 1; Female; Hyperglycemia; Insulin; Insulin Antibodies; Mice, Inbred NOD; Microscopy, Fluorescence; Vaccination; Epitopes; Autoimmunity


Description

The deposited article version contains attached the supplementary materials within the pdf.

Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease onset, increased its incidence, and worsened insulitis.

European Union’s (EU FP7) Large-Scale Focused Collaborative Research Project on Natural Immunomodulators as Novel Immunotherapies for Type 1 Diabetes grant: (NAIMIT, 241447).

Document Type Journal article
Language Portuguese
Contributor(s) ARCA
CC Licence
facebook logo  linkedin logo  twitter logo 
mendeley logo

Related documents